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Lapatinib (LAP), the tyrosine kinase inhibitor drug with moderate bioavailability, was characterized in terms of physicochemical
properties: acid-base characteristics, lipophilicity, and solubility. The highly lipophilic nature of the drug and its extremely low
water solubility (𝑆0 = 0.82 nM) limit the development of a parenteral formulation. In order to enhance solubility and bioavailability,
inclusion complex formation with cyclodextrins (CDs) is a promising method of choice.Therefore, LAP-CD interactions were also
studied by a multianalytical approach. The stability constants of LAP with native cyclodextrins, determined by UV spectroscopy,
identified the seven-membered 𝛽-CD as the most suitable host. Continuous variation method (Job’s plot) by 1H NMR showed
a 1 : 1 stoichiometry for the complexes. The geometry of the complex was elucidated by 2D ROESY NMR measurements and
molecular modeling, indicating that the partial molecular encapsulation includes the fluorophenyl ring of LAP. Phase-solubility
studies with four CDs, 𝛽-CD, (2-hydroxypropyl)-𝛽-cyclodextrin (HP-𝛽-CD), randomly methylated-𝛽- (RAMEB-) cyclodextrin,
and sulfobutylether-𝛽-cyclodextrin (SBE-𝛽-CD), show an AL type diagram and highly increased solubility via CD complexation.
The results are especially promising with SBE-𝛽-CD, exerting more than 600-fold gain in solubility.The equilibrium and structural
information presented herein can offer the molecular basis for an improved drug formulation with enhanced bioavailability.
1. Introduction
Lapatinib (LAP) (Figure 1) is a potent and selective inhibitor
of the epidermal growth factor receptor (EGFR) and human
epidermal growth factor receptor 2 (HER2) [1].
The drug is marketed as its ditosylate salt, in form of a
film-coated tablet (Tyverb/Tykerb). It is currently used in
combination therapy with capecitabine or letrozole for the
treatment of HER2-positive advanced or metastatic breast
cancer [2, 3]. The pharmacokinetic properties of LAP are
not optimal. Its oral bioavailability is moderate at best, it has
considerable interpatient variability [4], and it is significantly
affected by food intake. Both low-fat and high-fat diets
before LAP administration increased its systematic exposure
[4, 5]. Besides food intake, gastric pH also influences LAP
bioavailability. Higher gastric pH reduces LAP absorption;
therefore, concomitant use of proton-pump inhibitors (PPIs)
can decrease its bioavailability [6]. The recommended dose
of LAP is 1,250–1,500mg once daily, which means taking
5-6 tablets at once, reducing patient adherence to therapy.
Increasing the bioavailability of LAP could reduce the dose.
Thus, a novel formulation with high solubility and bioavail-
ability is currently an unmet medical need.
Enhancement of solubility and the concomitant bioavail-
ability can be achieved by variousmeans, such as solid disper-
sion, size reduction, cosolvency, polymorphism, formation of
water soluble prodrug, or complexes [7]. Cyclodextrin (CD)
complexation is one of themost extensively investigated ways
to improve drug solubility and bioavailability [8].
CDs are cyclic oligosaccharides comprising six, seven, or
eight D-glucose units (𝛼-, 𝛽-, and 𝛾-CD, resp.) that have been
recognized as pharmaceutical adjuvants for the past 20 years.
CDs have a hydrophilic surface responsible for their water
solubility and a hydrophobic, inner cavity, where lipophilic
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Figure 1: Chemical structure and numbering of LAP.
molecules with adequate dimensions can be accommodated
forming a noncovalently bonded host-guest complex, con-
ferring an increased aqueous solubility for the encapsulated
molecule. Besides native CDs, several modified derivatives
are also available, differing in nature, position of substituents,
and average degree of substitution, in order to enhance the
inclusion capacity and improve the physicochemical prop-
erties of the parent, native CDs [9, 10]. Many advantages of
inclusion complexation have been reported, such as increased
solubility, enhanced bioavailability, improved stability, taste
and odor masking, reduced volatility, and modified drug
release [11].
So far only a few attempts have been reported to improve
the bioavailability of LAP [12–14]. To the best of our knowl-
edge, LAP-CD inclusion complex characterization has yet
to be described, despite the fact that CD complexation has
been proven to increase the solubility, bioavailability, and
anticancer activity of other tyrosine kinase inhibitors erloti-
nib, gefitinib, imatinib, and so forth [15–19]; moreover,
sulfobutylether-𝛽-CD was used for solubilizing LAP in some
earlier studies [20, 21].
Here we report the quantified biorelevant physicochemi-
cal properties of LAP. On the basis of the protonation con-
stants, lipophilicity, and solubility parameters, we focus on
the characterization and optimization of complex formation
between various CDs and LAP. The information presented
herein can be useful for the development of a new, improved
LAP formulation.Themethods used in this study includeUV
and NMR spectroscopy, electrospray ionization-mass spec-
trometry (ESI-MS), phase-solubility, and molecular model-
ing.
2. Materials and Methods
2.1. Materials. All CDs (𝛼-CD, 𝛽-CD, 𝛾-CD, (2-hydroxypro-
pyl)-𝛽-CD (HP-𝛽-CD), random methylated 𝛽- (RAMEB-)
CD and sulfobutylether-𝛽-CD (SBE-CD)) were the products
of Cyclolab R&D Ltd., Hungary. Degree of substitution (DS)
of HP-𝛽-CD, RAMEB, and SBE-CD was ∼4.5, ∼12, and
6.5, respectively. LAP was purchased from Eurasia’s Ltd.,
India. Tris(hydroxymethyl)aminomethane (Tris), H3PO4,
KH2PO4, KOH,NaOH,HCl, andKClwere of analytical grade
from commercial suppliers. D2O, DCl, dimethylsulfoxide
(DMSO), hexadeuterated dimethylsulfoxide (DMSO-𝑑6),
and n-octanol were obtained from Sigma-Aldrich, while
MeOH was from Merck. Ultrapure, deionized water was
prepared by a Milli-Q Direct 8 Millipore system.
2.2. Determination of Protonation Constant by UV-pH Titra-
tion. The log𝐾 value of LAP was determined by UV-
pH titration, using the D-PAS ultraviolet spectropho-
tometer attached to a GLpKa instrument (Sirius Analytical
Instruments Ltd., Forest Row, UK). Multiwavelength UV
absorbance of the sample solutionwasmonitored throughout
the titration using the fiber-optic probe in situ [22]. The UV-
pH titrations were carried out under nitrogen atmosphere at
constant ionic strength (𝐼 = 0.15MKCl) and temperature
(𝑡 = 25.0 ± 0.5∘C). Due to the very low solubility of LAP,
the cosolvent method was used to determine its log𝐾 value.
The cosolvent protonation constants (log𝐾󸀠 values) were
determined in six differentMeOH-watermixtures within 23–
43% (w/w). A stock LAP solution of 7mM concentration was
prepared in DMSO. In each experiment, 75𝜇L of the stock
solutions was transferred into sample vials containing 15mL
of 0.15MKCl solution to achieve the required sample concen-
tration. In each experiment, the acidity of the sample solution
was adjusted using 0.5M HCl to about pH∗ 2.5 and then
titrated with 0.5M KOH to about pH∗ 9. Spectral data were
recorded in the 200–700 nm region after each pH measure-
ment. About 20 pH readings and absorption spectra were
collected from each titration. The log𝐾󸀠 values were calcu-
lated by RefinementPro software.
The measured log𝐾󸀠 values in MeOH-water solutions
were then extrapolated to aqueous condition (zero MeOH
concentration) according to the Yasuda-Shedlovsky proce-
dure [23]. The Yasuda-Shedlovsky extrapolation method is
based on the linear relation between log𝐾󸀠 and the dielectric
constant (𝜀) of the cosolvent mixture:
log𝐾󸀠 + log [H2O] =
𝑎
𝜀 + 𝑏, (1)
where 𝜀 is the dielectric constant, and log[H2O] is the molar
water concentration of the givenMeOH-watermixture.Three
parallel measurements were carried out.
2.3. Determination of the Intrinsic Solubility by Chasing Equi-
librium Solubility Method (Cheqsol). The thermodynamic
solubility of the nonionized form of the samples was deter-
mined by the Chasing Equilibrium Solubility (CheqSol)
method [24]. The apparatus used to perform the solubility
determinations was a GLpKa titrator and a D-PAS spectrom-
eter controlled by RefinementPro and CheqSol software (Sir-
ius, Forest Row, UK). The titrations were performed under
nitrogen atmosphere, at 0.15M ionic strength and 25.0±0.5∘C
using standardized 0.5M HCl and 0.5M KOH solutions.
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Three parallel measurements were carried out. The imple-
mentation of the experiment is described in more detail in
our previous articles [19, 25].
2.4. Partition Coefficient Measurement by the Stir-Flask
Method. The distribution coefficients were measured from
the absorbance of the molecules before and after partitioning
using standard stir-flask method as we previously reported
[26].
The partition coefficient (𝑃) cannot be measured directly
due to the high log𝑃 value of LAP.Therefore, the distribution
coefficient (𝐷) was determined at acidic pH (pH = 2), where
themolecule is in dicationic form, and at two other pH values
at pH 5.83 and 6.11.Three parallel measurements were carried
out at each pH. The pH was measured using a Metrohm
6.0204.100 combined pH glass electrode and a Metrohm 780
pH meter. The water/n-octanol phase ratio varied between
250 and 600. The log𝑃 values of each macrospecies were
calculated based on the following equation:
𝐷pH = 𝜒𝑖𝑃𝑖 = 𝜒LAP2+𝑃LAP
2+ ∗ 𝜒LAP+𝑃LAP
+ ∗ 𝜒LAP𝑃LAP, (2)
where 𝜒 is the mole fraction of the corresponding macrospe-
cies of the charge indicated.
2.5. Determination of Cyclodextrin Complex Stability by UV
Spectroscopy. UV spectroscopic measurements were carried
out on a Jasco V-550 diode-array spectrometer (Jasco, Japan)
with 10mm quartz cuvettes at 25∘C.
LAP was titrated with a constant amount of native CDs
(𝛼-, 𝛽-, and 𝛾-CD) at pH = 2 using 0.01MHCl as solvent.
A stock solution of each CD was combined with different
volumes of LAP solutions and filled to the same volume. The
UV spectra were measured against a blind solution. Three
parallel measurements were carried out for each CD. The
complex formation equilibrium can be characterized by the
following complex stability constant:
𝐾stab =
[CD-LAP]
[CD] [LAP] , (3)
where [CD], [LAP], and [CD-LAP] are the equilibrium
concentrations of the CD, LAP, and the complex, respectively.
Since the total concentrations of CD ([CD]𝑇) and LAP
([LAP]𝑇) are known, assuming 1 : 1 stoichiometry, we can use
the following relationships:
[CD]𝑇 = [CD] + [CD-LAP]
[LAP]𝑇 = [LAP] + [CD-LAP] .
(4)
Since absorbance of any of the CDs is negligible and no
association other than the CD-LAP formation takes place,
it can be safely assumed that only LAP and the complex
contribute significantly to the absorbance; therefore, the
measured absorbance at any given wavelength is the weighed
linear combination of the two absorbances (𝜀0 and 𝜀1 being
the molar extinction coefficients of LAP and the complex at a
given wavelength, resp.):
𝐴 = 𝜀0 [LAP] + 𝜀1 [CD-LAP] . (5)
Since the equilibrium concentration of LAP can be expressed
in terms of the total LAP and the complex concentrations, the
above equation takes on the following form:
𝐴 = 𝜀0 [LAP]𝑇 + (𝜀1 − 𝜀0) [CD-LAP] . (6)
The complex concentration can be expressedwith the stability
constant (𝐾stab) and the total concentrations:
𝐾stab =
[CD-LAP]
([CD]𝑇 − [CD-LAP]) ([LAP]𝑇 − [CD-LAP])
. (7)
Solving the above quadratic equation for [CD-LAP] one can
derive an equation for absorbance (using (6)), which, if fitted
onto the data, provides the complex stability constant:
𝐴 = 𝜀0 [LAP]𝑇
+ (𝜀1 − 𝜀0)
(𝐾stab [CD]𝑇 + 𝐾stab [LAP]𝑇 + 1) − √(𝐾stab [CD]𝑇 + 𝐾stab [LAP]𝑇 + 1)2 − 4𝐾stab2 [CD]𝑇 [LAP]𝑇
2𝐾stab
.
(8)
Multiple fitting was performed with Opium program.
2.6. NMR Measurements. All NMR measurements were
carried out on an Agilent/Varian VNMRS spectrometer
(600MHz for 1H) with a 5mm inverse-detection gradient
probehead inD2O/DMSO-𝑑6 7/3 (v/v)mixtures at 25∘C. pD∗
was set to 2 using DCl solution. Addition of DMSO-𝑑6 was
necessary due to the low solubility of LAP in aqueous solvents,
even at acidic pH. The chemical shifts were referenced to the
solvent signal of internal DMSO. Standard pulse sequences
and processing routines available in VnmrJ 2.2C/Chempack
4.0 were used.
For determination of complex stoichiometry, Job’s con-
tinuous variation method was used. Solutions were prepared
from LAP and 𝛽-CD in complementary amounts, tomake up
a 1.5mM summary concentration. The solutions were mixed
in different ratios and the 1H NMR spectra were recorded
after 24 h.
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The average extent of penetration and the direction of
inclusion were investigated by 2D ROESYNMR. Intermolec-
ular NOEs between LAP and CD protons directly involved
in the host-guest interaction were detected as cross-peaks.
In these experiments, the samples contained 1mM LAP and
2mM 𝛽-CD. The ROESY spectrum was recorded applying
a sweep width of 6 kHz and a spinlock of 3 kHz for a
mixing time of 300ms. 256 increments were collected with
32 repetitions and the measured data matrix was processed
as a matrix of 4K (𝐹2) by 1K (𝐹1) data points.
2.7. ESI-MS Experiments. High resolution accurate mass
of LAP-𝛽-CD inclusion complex was determined with an
Agilent 6230 time of flight (TOF)mass spectrometer (Agilent,
Germany). Samples were introduced by the Agilent 1260
Infinity LC system, and the mass spectrometer was operated
in conjunction with a Jet Stream electrospray ion source in
positive ion mode. Reference masses of m/z = 121.050873
and 922.009798 were used to calibrate the mass axis during
analysis.The following ion source parameterswere employed:
flow and temperature of the drying gas: 10 L/min and 320∘C;
pressure of the nebulizer gas (N2): 45 psi; capillary voltage:
3000V; nozzle voltage: 500V; sheath gas flow and tempera-
ture: 10 L/min and 320∘C, respectively. TOF-MS parameters
were as follows: fragmentor voltage: 300V; skimmer poten-
tial: 170V; OCT 1 RF Vpp: 750V. 1 𝜇L of sample solution,
containing 1mM LAP and 1mM 𝛽-CD, was directly injected
into themass spectrometer. Data were acquired in a 100–3000
m/zmass range and peaks of the hypothesized complex were
searched for in the 1000–3000m/z interval.Mass spectrawere
processed by Agilent MassHunter B.04.00 software.
2.8. Phase-Solubility Studies. LAP phase-solubility studies
were performed according to the method described by
Higuchi and Connors [27]. Excess amount of LAP (5-
6mg) was added to 5mL stock solution with increasing
concentrations of different CDs (𝛽-CD, HP-𝛽-CD, RAMEB,
and SBE-CD) at pH 2.0 at 0.15M ionic strength.The obtained
suspensions were stirred for 24 hours. After sedimentation,
LAP concentrations were measured from the supernatant
spectrophotometrically on a Jasco V-550 instrument at
269 nm.Three parallel measurements were carried out.
Assuming 1 : 1 stoichiometry, the stability constant of the
complex (𝐾stab) can be determined using the phase-solubility
diagram according to the following equation:
𝐾stab =
slope
𝑆0 (1 − slope)
, (9)
where 𝑆0 is the intrinsic solubility of LAP in the absence of
CDs.
2.9. Molecular Modeling. Molecular modeling study was
performed as previously reported [19, 28, 29] by using
the semiempirical PM3 method of Hyperchem Professional
software (version 8.0). The initial structures of neutral LAP
and 𝛽-CD were constructed with the help of Hyperchem 8.0
and optimized with PM3. A docking procedure was used to
calculate the energy of the complex. LAP was moved into
the CD cavity from the wider rim, step-by-step, performing a
geometry optimization after each step until the conformation
with the lowest energy was achieved. The docking procedure
was repeated using different starting positions, and the lowest
achieved energy was considered as the optimal geometry of
the complex.
The stability of the complex was estimated from the
formation energy:
Δ𝐸 = 𝐸complex − (𝐸LAP + 𝐸CD) . (10)
3. Results and Discussion
3.1. Physicochemical Characterization of LAP. Determination
of the physicochemical properties of drugs is crucial to
understand the pharmacokinetic behavior at the molecular
level. Therefore, protonation constants, octanol/water parti-
tion coefficient, and the intrinsic solubility of LAPwere deter-
mined. Due to the very low solubility of LAP, the protonation
constants can only be determined by UV-pH titration with
mixed-solvent procedure (Figure 2(a)). In ourmeasurements,
the MeOH-water cosolvent system was used, where the
apparent protonation constants (log𝐾󸀠 values) were deter-
mined in six different mixtures; then the aqueous log𝐾s were
obtained by extrapolation using Yasuda-Shedlovsky method
(see (1)) taking into account the dielectric constant of the
different cosolvent mixtures (Figure 2(b)). This way log𝐾1 =
7.72 ± 0.07 and log𝐾2 = 5.08 ± 0.05 values were obtained.
Using the protonation constants, the distribution curves
for protonation macrospecies of LAP can be depicted as a
function of the pH (Figure 3(a)). The diagram shows that, in
acidic media, at the pH of the stomach, the dicationic form
is overwhelmingly dominant. The compound exists mainly
in monocationic form at the pH of the blood (67.4%). Above
pH 8, the neutral form dominates, which plays a crucial role
in the transport mechanism in general, assuming that orally
administrated LAP is absorbed mainly from the intestine.
Lipophilicity of LAP was characterized in terms of par-
tition coefficient, which is the most widely used descriptor
of lipophilicity in QSAR studies [30]. The working range of
the used stir-flask method is −4 to +4 in log𝐷 values, limited
by the accuracy of the phase volume measurement. Based on
this fact, the octanol/water partition coefficient at pH values
where the nonionized form dominates cannot be measured
directly due to the very high log𝑃 value of LAP. Therefore,
the log𝐷 values were measured at lower pHs. At pH 2, where
the molecule is practically 100% dicationic, the measured
log𝐷pH 2 = 2.71 ± 0.06 characterizes the lipophilicity of the
dicationic species. From log𝐷 values at pH 5.83 (3.67±0.07),
pH 6.11 (3.90 ± 0.08), and pH 2 (2.71 ± 0.06), the log𝑃 value
of the monocationic and neutral species could be calculated
using (2).The values are summarized in Table 1, while the pH-
dependent lipophilicity profile of LAP is in Figure 3(b).
These values indicate that LAP is an extremely lipophilic
molecule and even the dicationic form has the capability to
penetrate membranes by passive diffusion. These high log𝑃
values also explain the ability of LAP to cross the blood-brain
barrier, which could be a further therapeutic approach in
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Figure 2: Determination of protonation constants of LAP by (a) UV/pH titration of LAP in 43/57 (w/w%) methanol/water mixture and (b)
Yasuda-Shedlovsky extrapolation.
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Figure 3: (a) Logarithmic distribution diagram for the LAPprotonationmacrospecies. (b) Contribution of the LAPprotonationmacrospecies
to the lipophilicity profile (in black broad line).
brainmetastasis [31]. As a part of our LAPprofiling, its intrin-
sic solubility (the equilibrium solubility of the nonionized
form) was measured by the CheqSol method, which resulted
in a value of only 0.48 ng/mL. LAP is a class II drug in the
Biopharmaceutics Classification System, being of low water
solubility and high permeability, which is in good agreement
with our determined physicochemical values. These data
quantify that the very poor solubility is the Achilles heel
of the LAP administration. It is the root cause for the low
bioavailability of the drug the necessity of taking very high
doses. These problems could be alleviated by enhancing LAP
solubility through CD inclusion complexation. For further
pharmaceutical formulation development, optimization of
CD-complex formation is crucial; therefore, interactions
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Figure 4: Determination of LAP-𝛽-CD stoichiometry. (a) Representative Job plot diagrams of selected LAP protons. (b) Representative mass
spectrum of a LAP-𝛽-CD sample.
Table 1: Calculated log𝑃 values of the different LAP macrospecies.
Macrospecies log𝑃
Dicationic 2.71 ± 0.07
Monocationic 3.15 ± 0.10
Neutral 5.49 ± 0.10
between LAP and CDs were characterized in solution with
a wide variety of complementary analytical techniques
and approaches, such as phase-solubility studies, 1H and
2D NMR techniques, UV spectroscopy, and electrospray
ionization-time of flight-mass spectrometry (ESI-TOF-MS).
3.2. Determination of LAP-𝛽-CD Stoichiometry: NMR Job Plot
and ESI-TOF-MS Studies. In order to draw adequate conclu-
sions on the inclusion process, the knowledge of selector-
selectand complexation stoichiometry is a prerequisite. The
general method to determine complex stoichiometry is Job’s
continuous variation method. In this experiment, the 1H
NMR chemical shifts (𝛿) were measured at different LAP
concentration/𝛽-CD concentration (𝑐LAP/𝑐CD) ratios, while
the sum of 𝑐LAP + 𝑐CD was kept constant. The calculated
factors (Δ𝛿𝜒LAP) were plotted as a function of LAP molar
ratio (𝜒LAP). In all cases, the resulting Job plot diagrams
showed maxima at 0.5, indicating the typical 1 : 1 binding
stoichiometry. Representative Job plot curves of LAP and 𝛽-
CD are shown in Figure 4(a).
The complex stoichiometry was also studied by ESI-TOF-
MS technique, which provides a powerful means to study
noncovalent host-guest inclusion complexes between a CD
and the guest molecule [32]. A large number of publications
prove that a simple, fast ESI-MS analysis is suitable for the de-
termination of inclusion complex stoichiometry [15, 19, 33];
however, ESI-MS studies imply the question whether the
observed peaks represent actual inclusion complexes or
rather electrostatic adducts formed during the electrospray
process [34], if, however, additional adequate techniques
prove that the complex formation ESI-MS is straightforward
way to determine complex stoichiometry. Analyzing the MS
spectra in the 100–1500m/z range, the protonated molecular
ion of the uncomplexed LAP (m/z 581.1419 [M+H]+), their
source fragment ion (m/z 458.1027 [M+H]+), and the charac-
teristic m/z values of uncomplexed 𝛽-CD (m/z 1135.3732
[M+H]+, 1157.3531 [M+Na]+) can be observed. Figure 4(b)
shows the renormalized upper part (1500–3000 m/z) of the
mass spectrum of a sample containing LAP and 𝛽-CD in 1 : 2
molar ratio. The observed signal at m/z 1715.5157 with gen-
erated C71H96ClFN4O39S molecular formula corresponds to
the LAP-𝛽-CD 1 : 1 inclusion complex, whichmeans that ESI-
TOF-MS confirms the NMR Job result, verifying the 1 : 1 stoi-
chiometry.
3.3. Determination of Stability Constant by UV. UV spec-
troscopy can be a sensitive technique to characterize the CD
inclusion complexes, provided that the guestmolecule under-
goes the significant absorption changes upon complexation.
This technique can be used for the determination of CD
stability constant of molecules with low solubility as well.
Using (8), the stability constants betweenLAP andnativeCDs
were determined to select themost suitable host.The stability
constants determined at pH 2 are listed in Table 2.
Based on these data, we can conclude that, concerning
the size, the seven-membered 𝛽-CD is the most suitable host
molecule for complexation. Thus, further experiments were
carried out with 𝛽-CD and its derivatives.
3.4. Structure of the LAP-𝛽-CD Complex. 2D ROESY NMR
combined with molecular modeling is an appropriate way
Journal of Chemistry 7
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Figure 5: Determination of the LAP–𝛽-CD inclusion complex geometry. (a) Expansion of 2DROESYNMR spectrum. (b) Energy-minimized
structure of the complex based on the result of molecular modeling study.
Table 2: Determined 𝐾stab values at pH 2 for different LAP-CD
complexes with UV spectroscopy.
CD 𝐾stab (M−1)
𝛼-CD 46 ± 8
𝛽-CD 121 ± 12
𝛾-CD 89 ± 6
to characterize the geometry of inclusion complexes. ROESY
experiment offers valuable information on spatial proximity
between protons of the host and guestmolecules by observing
intermolecular dipolar cross-correlations, while molecular
modeling seeks the energy-minimized structure, which can
be visualized at the atomic level [19, 35, 36].
2D NMR ROESY spectra for LAP–𝛽-CD inclusion com-
plex were recorded at pD∗ 2, where LAP exhibits an appro-
priate solubility. The expansion of this 2D spectrum in
Figure 5(a) contains an intramolecular cross-peak between
H3 (6.76 ppm) and H6 (3.52 ppm) nuclei of LAP. From
the viewpoint of encapsulation intermolecular cross-peaks
of the fluorophenyl protons (H37,38,39) with the inner H-3
(3.68 ppm) and H-5 (3.58 ppm) protons of 𝛽-CD are crucial.
Due to the fact that the H39 (7.49 ppm) proton of LAP gives
a stronger cross-peak with the H-3 proton of the CD, we can
assume that the fluorophenyl moiety is accommodated in the
CD cavity from the wider rim. Based on ROESY data,
molecularmodeling at PM3 level was carried out.The energy-
minimization structure is depicted in Figure 5(b).The energy
of formation of the complex was found −10.7 kcal/mol, indi-
cating that complex formation is thermodynamically favored.
3.5. Phase-Solubility Studies. Phase-solubility analysis accord-
ing to Higuchi and Connors is an appropriate technique
to demonstrate changes in drug solubility. Moreover, sta-
bility constants and stoichiometry can also be determined
[9]. Upon addition of increasing amounts of CDs (𝛽-CD,
Table 3:𝐾stab values calculated from phase-solubility studies for the
CDs employed.
CD 𝐾stab (M−1)
𝛽-CD 131 ± 9
RAMEB 331 ± 15
HP-𝛽-CD 537 ± 20
SBE-CD 31622 ± 120
RAMEB, HP-𝛽-CD, and SBE-CD) at pH 2, linear solubility
enhancement was observed for LAP, regardless of the CD
employed (Figure 6).
The resulting AL-type linear positive isotherms reveal
1 : 1 binding stoichiometry, further supporting Job plot and
ESI-TOF-MS results. The 𝐾stab values calculated by (9) are
summarized in Table 3.
The determined𝐾stab value for𝛽-CD byUV spectroscopy
and phase-solubility is in agreement. Moreover similar
stability constants were determined for other cyclodextrin
complexes of tyrosine kinase inhibitors [15, 16, 19].The values
in Table 3 show that the substitution of the 𝛽-CD enhances
inclusion complex formation stability as observed also in the
case of erlotinib [19]. However, in the case of imatinib, the
methylation of the native 𝛽-CD reduced the stability of the
complex [15], which can be explained by the structural differ-
ences of these anticancer drugs. The largest binding constant
was observed for SBE-𝛽-CD, which is totally ionized under
the applied conditions. Thus, the reason of the more stable
complex is the additional electrostatic attractions between
the multiply negatively charged hosts and the dicationic LAP.
Concerning the solubility enhancing capabilities, it can be
stated that CDderivatives enhance the LAP solubility due pri-
marily to the inclusion phenomenon, which can be extended
by electrostatic forces. The results are especially promising
with SBE-𝛽-CDwheremore than 600-fold solubility increase
could be achieved.
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Figure 6: Phase-solubility diagrams of LAP-CD complexes.
4. Conclusion
LAP, the anticancer drug, was characterized in terms of
lipophilicity, solubility, acid-base, and CD-complex forma-
tion properties, using complementary methods, such as
UV, NMR, phase-solubility, and molecular modeling. An
important practical result of this work is that CDs, especially
the substituted derivatives, significantly increase the LAP
solubility, which can be a starting point of a new LAP
formulation of improved bioavailability.
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